Actual costs of cancer drugs in 15 European countries

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages 18-20

  van Harten, Wim H ^a   Wind, Anke ^a   de Paoli, Paolo ^b   Saghatchian, Mahasti ^c   Oberst, Simon ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Cambridge Cancer Trials Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG COST; DRUG INDUSTRY; ECONOMICS; EUROPE; HUMAN; QUESTIONNAIRE;

ANTINEOPLASTIC AGENTS; DRUG COSTS; DRUG INDUSTRY; EUROPE; HUMANS; SURVEYS AND QUESTIONNAIRES;

EID: 84955240467     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00486-6     Document Type: Note

References (8)

1. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013, 14:1165-1174.
3. Effective new anti-cancer drugs, but the funding system is creaking at the seams. 2015 Dutch Cancer Society (KWF), (accessed Sept 2, 2015). https://www.kwf.nl/SiteCollectionDocuments/english-summary-signalingreport-expensive-cancermedication.pdf.
4. Ramsey S How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs. Health Affairs (Millwood) 2015, 34:571-575.
5. Schnipper L, Davidson N, Wollins D, et al. American Society for Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015, 33:2563-2577.
6. Cherny N, Sullivan R, Dafni U, et al. A standardized generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for medical oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015, 26:1547-1573.
7. Celis JE, Ringborg U Cancer Core Europe: a first step towards a virtual cancer institute in Europe?. Mol Oncol 2014, 8:1161-1162.
8. Lopes S, Marty C, Berdai D PHIS pharma profile France (accessed Oct 30, 2015). http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/PHIS_Pharma%20Profile%20FR_2011_final.pdf.